Manipulating the immune system: Humoral versus cell-mediated immunity

Advanced Drug Delivery Reviews

Volumn 51, Issue 1-3, 2001, Pages 43-54

  McNeela, Edel A ^a   Mills, Kingston H G ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Acquired immunity; Adjuvant; Antibody; Immunomodulator; Infectious pathogen; Innate immunity; Th1 Th2 cell; Vaccine delivery system

Indexed keywords

ANTIGENS; BACTERIA; CELLS; DISEASES; DNA; PROTEINS; VACCINES; VIRUSES;

HUMORAL IMMUNE EFFECTOR MECHANISMS;

IMMUNOLOGY;

CHITOSAN; CHOLERA TOXIN; CYTOKINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; LIVE VACCINE; PHOSPHORYL LIPID A; POLYGLACTIN;

CELLULAR IMMUNITY; CPG ISLAND; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; HUMAN; HUMORAL IMMUNITY; LIPID VESICLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, CELLULAR; VACCINES; VACCINES, DNA;

EID: 0035940317     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00169-7     Document Type: Review

References (64)

1. Vaccines for mucosal immunity to combat emerging infectious diseases
2. Recognition of foreign antigen by T cells and their role in immune protection
3. The expanding universe of T-cell subsets: Th1, Th2 and more
4. Innate immunity: The virtues of a nonclonal system of recognition
5. + Th1 clones with cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor
6. Interferon-γ enhances expression of secretory component, the epithelial receptor for polymeric immunoglobulins
7. + Th1 cells
8. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable polymers: Effect of formulation and route of immunization on induction of Th1 and Th2 cells
9. Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles
10. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes
11. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits
12. 197) of diphtheria toxin with chitosan enhances local and systemic antibodies and Th2 responses following nasal delivery
13. Immunological activity of chitin and its derivatives
14. Stimulation of cytokine production in mice using deacetylated chitin
15. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice
16. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1
17. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration
18. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen
19. A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar typhi and typhimurium live vector vaccines delivered by mucosal routes in the murine model
20. Engineering the microflora to vaccinate the mucosa: Serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli
21. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice
22. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice
23. Activation of systemic and mucosal immune response following nasal administration of liposomes
24. A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses
25. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
26. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses
27. Interferon-γ inductive effect of liposomes as an immunoadjuvant
28. The immunostimulatory complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
29. Immune-stimulating complexes induce an IL-12 dependent cascade of innate immune responses
30. Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses
31. Protective DNA immunization against Chlamydia pneumoniae
32. Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization
33. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
34. Mucosal immunization with DNA-liposome complexes
35. Naked DNA when co-administered intranasally with heat-labile enterotoxin of Escherichia coli primes effectively for systemic B- and T-cell responses to the encoded antigen
36. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
37. Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
38. Interleukin 12 and innate molecules for enhanced mucosal immunity
39. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens
40. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1
41. Use of intranasal IL-12 to target predominately Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin
42. Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10
43. Combined nasal administration of encephalitogenic myelin basic protein peptide 68-86 and IL-10 suppressed incipient experimental allergic encephalomyelitis in Lewis rats
44. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
45. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic
46. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli heat labile enterotoxin
47. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
48. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
49. Ceramide signalling and the immune response
50. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)
51. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: Distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity
52. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression
53. Helper Th1 and Th2 responses following mucosal or systemic immunization with cholera toxin
54. Cholera toxin induces maturation of human dendritic cells and licenses them for Th2 priming
55. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T cell responses against HIV-1 gag-p55
56. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G)
57. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant
58. Intranasal booster vaccination against diphtheria and tetanus in man
59. Evaluation of the live attenuated cpts 248/04 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young or older adults
60. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers
61. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults
62. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine
63. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
64. Whole cell but not acellular pertussis vaccines induce convulsive activity in mice: Evidence of a role for toxin-induced interleukin-1β in a new murine model for analysis of neuronal side effects of vaccination